April, 2016. Certain shareholders of Molecular Partners AG (SIX: MOLN) (Molecular Partners), including employees, consultants, members of the board of directors of Molecular Partners and certain venture capital shareholders successfully completed a private placement of 1,100,000 shares via an accelerated book building transaction for an aggregate sales price of approximately CHF 30 million. The share placement will allow the employees and consultants of Molecular Partners to cover the income and wealth taxes as well as social security contributions incurred in connection with the exercise of options, which have been granted to them as important part of their compensation packages.

Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPins.

Molecular Partners was advised by Homburger in this transaction. The Homburger team was led by partner Dieter Gericke (Corporate | M&A) and included partner Stefan Oesterhelt (Tax) and associate Karin Mattle (Corporate | M&A).